New phase 3 results highlight potential alternative for adults switching from complex regimens

More than 200 participants enrolled as company targets topline data by end of 2026

Oral therapy authorised for ER‑positive, HER2‑negative metastatic disease with ESR1 mutations

Erythromelalgia treatment gains regulatory support following EMA decision

PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens

QUASAR long‑term extension results highlight durable clinical and endoscopic outcomes

MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups

Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD

Basque company becomes first authorised under new European SoHO rules

European Commission backs first ultra‑long‑acting biologic for respiratory disease